-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Tizoxanide-[d4]
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1246817-56-0.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1246817-56-0 |
| Description | Tizoxanide-[d4] is the labelled analogue of Tizoxanide. Tizoxanide is the active metabolite of nitazoxanide, an anti-infective that has been approved for the treatment of diarrhea caused by Giardia lamblia or Crytosporidium parvum. Tizoxanide is active against anaerobic bacteria, protozoan parasites, and viruses. |
Product Information
| Synonyms | Tizoxanide D4; 2-Hydroxy-N-(5-nitro-2-thiazolyl)benzamide-d4 |
| IUPAC Name | 2,3,4,5-tetradeuterio-6-hydroxy-N-(5-nitro-1,3-thiazol-2-yl)benzamide |
| Molecular Weight | 269.27 |
| Molecular Formula | C10H3D4N3O4S |
| Canonical SMILES | C1=CC=C(C(=C1)C(=O)NC2=NC=C(S2)[N+](=O)[O-])O |
| InChI | InChI=1S/C10H7N3O4S/c14-7-4-2-1-3-6(7)9(15)12-10-11-5-8(18-10)13(16)17/h1-5,14H,(H,11,12,15)/i1D,2D,3D,4D |
| InChIKey | FDTZUTSGGSRHQF-RHQRLBAQSA-N |
| Melting Point | >200°C (dec.) |
| Purity | 95% by HPLC; 98% atom D |
| Density | 1.6±0.1 g/cm3 |
| Solubility | Soluble in DMSO, Methanol |
| Appearance | Brown Solid |
| Storage | Store at -20°C |
| Complexity | 336 |
| Exact Mass | 269.04083387 |
| Index Of Refraction | 1.750 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| Target | Bacterial; HIV; Autophagy |
| XLogP3-AA | 3.2 |
